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Abstract
Background: While incarceration has consistently been associated with a higher risk of HIV
infection for individuals who use injection drugs (IDU), the effect of incarceration on the post-
release risk environment remains poorly described. We sought to assess the impact of
incarceration on risk factors for HIV infection after release from prison in a sample of active IDU
in Vancouver, Canada.
Methods: Using a prospective cohort of community-recruited IDU followed from May 1, 1996 to
November 30, 2005, we examined contingency tables and performed linear growth curve analyses
to assess changes in the prevalence of independent risk factors for HIV infection from before to
after a period of incarceration among participants reporting incarceration and a matched control
group.
Results: Of the 1603 participants followed-up over the study period, 147 (9.2%) were eligible for
an analysis of post-incarceration risk behaviours and 742 (46.3%) were used as matched controls.
Significant differences were found in one or both groups for the prevalence of frequent cocaine
injection, requiring help injecting, binge drug use, residence in the HIV outbreak epicentre, sex-
trade participation and syringe sharing (all p < 0.05) after incarceration. In linear growth curve
adjusted for age, gender and ethnicity, syringe sharing was significantly more common in those
recently released from prison (p = 0.03) than in the control group.
Conclusion: In a sample of Canadian IDU, we did not observe any effect of incarceration on the
prevalence of several behaviours that are risk factors for HIV infection, including intensity of drug
use or participation in the sex trade. However, those recently released from prison were more
likely to report syringe sharing that those in a matched control group.
Background
Incarceration is common among injection drug users
(IDU) and has consistently been associated with drug-
related harms, especially infection with blood-borne
pathogens like hepatitis C and HIV. [1-3] While many
IDU cease drug use upon imprisonment,[4,5] those that
Published: 27 May 2009
BMC Public Health 2009, 9:156 doi:10.1186/1471-2458-9-156
Received: 12 November 2008
Accepted: 27 May 2009
This article is available from: http://www.biomedcentral.com/1471-2458/9/156
© 2009 Milloy et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2009, 9:156 http://www.biomedcentral.com/1471-2458/9/156
Page 2 of 7
(page number not for citation purposes)
persist do so in environments of elevated risk. In many
penal facilities, including those in the United States, Can-
ada, Australia and the United Kingdom, harm reduction
measures, such as the distribution of sterile syringes, are
unavailable and the possession of injection equipment is
outlawed. [6,7] Epidemiological surveys of prisoners in a
variety of settings, including the United Kingdom, [8-11]
Greece[12] and Thailand[13,14] identified endemic use
of contaminated contraband syringes. Contact tracing
investigations found this dynamic fuelled prison-based
HIV outbreaks in Australia,[15] Russia,[16] Lithuania[17]
and Scotland. [1]
Although the link between imprisonment and HIV infec-
tion is robust and well described, the possible effects of
incarceration on post-release behaviours of IDU and their
HIV risk environment remain largely undetermined. [18]
Findings from related inquiries into sexual risk factors for
ex-prisoners suggest the experience of incarceration, tran-
sition to non-correctional settings and reintegration into
communities all influence post-release behaviours. [19-
21] While these studies are primarily concerned with indi-
vidual-level sexual risks, newly-released prisoners often
face difficulties finding employment,[22,23] securing
housing,[22,24] reestablishing social supports,[25,26]
accessing healthcare,[22,27] and enduring discrimina-
tion,[28] and these factors are known to structure HIV
risk. [29,30] However, very little attention has been paid
to the post-release trajectory of IDU or the specific deter-
minants of their risk environment.
We are unaware of any analyses that identify the effect of
incarceration on the risk factors for HIV infection follow-
ing release from prison or analyses that describe the spe-
cific individual, social and structural determinants of the
post-release risk environment for IDU. Thus, in the cur-
rent analysis, we sought to determine the possible effect of
imprisonment on the post-release risk environment by
identifying the prevalence of independent risk factors for
HIV infection before and after a period of incarceration as
compared to a non-incarcerated matched control group.
Methods
In May 1996, the Vancouver Injection Drug User Study
(VIDUS) began recruiting IDU through self-referral and
street outreach. This prospective cohort study has been
previously been described in detail. [31] In brief, individ-
uals were eligible for recruitment if they had injected
drugs at least once in the previous month, resided in
greater Vancouver and provided written informed con-
sent. At baseline and every six months, participants pro-
vide venous blood samples and complete an interviewer-
administered questionnaire. This structured question-
naire elicits demographic data, information about recent
drug use patterns, HIV risk behaviours, encounters with
the criminal justice system and experiences in addiction
treatment and other health-care settings. All participants
are given a $20 stipend at each visit. This study has
received approval from the Providence Health Care/Uni-
versity of British Columbia Research Ethics Board.
To inform our analysis of HIV risk factors, we first identi-
fied all participants who reported being incarcerated in a
municipal jail, provincial prison or federal penitentiary
overnight or longer since initiating injection drug use, a
definition consistent with previous analyses. [32,33]
Among these individuals, only those who had completed
a study visit both before and after this incarceration epi-
sode were eligible for an analysis of post-release risk
behaviour. Using frequency matching, participants who
had completed identical follow-up visits and did not
report recent incarceration at all during this period were
included in the control group. (Controls could have been
incarcerated at other times during the follow-up period.)
We then examined if there were significant differences
between the two groups with regards to age, gender and
ethnicity (Aboriginal vs. non-Aboriginal) using χ2 tests
and Wilcoxon rank-sum tests. We repeated these tests to
compare individuals included as cases or controls to par-
ticipants not included in the final analytic sample.
Next, we selected explanatory variables that had previ-
ously been identified as implicated in the transmission of
HIV in this setting: daily cocaine injection (yes vs.
no);[34] daily injection of a mixture of heroin and cocaine
("speedball") (yes vs. no);[35] requiring help injecting
(yes vs. no);[36,37] binge drug use (yes vs. no);[38] unsta-
ble housing (yes vs. no);[34] having sought and been
denied addiction treatment (yes vs. no);[39] residence in
the city's HIV epicenter, the Downtown Eastside (DTES)
(yes vs. no);[31] public drug use (yes vs. no);[40] partici-
pation in the sex trade (yes vs. no);[36] and syringe shar-
ing (yes vs. no). We also included consistent condom use
with regular sexual partners (yes vs. no) and consistent
condom use with casual sexual partners (yes vs. no). As in
previous work, frequent drug use was defined as once or
more per day. [41] Unstable housing was defined as living
in a single-room occupancy hotel room, a shelter, or being
homeless. [41] All variables referred to the previous six
months except unstable housing, which referred to cur-
rent conditions.
To test for differences between pre- and post-incarceration
periods between those incarcerated and the control group,
we used McNemar's test to examine the proportion of
individuals reporting each risk factor in each group. To
test for differences over time and between groups, we con-
structed linear growth curve models for each risk factor in
which a statistically significant trend was observed in one
or both groups. Commonly used in longitudinal observa-
tional research, the linear growth curve technique enablesBMC Public Health 2009, 9:156 http://www.biomedcentral.com/1471-2458/9/156
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the identification of changes over time by using an inter-
action term in the model to determine if those changes are
significant. [42,43] In each linear growth curve model, the
slope represents the differences in outcomes by group
(incarcerated vs. control) over time (before vs. after); the
p-value represents the significance of the interaction term.
In addition, to control for potential confounding, an a pri-
ori model fitting approach was used in which each model
was adjusted for age, gender and ethnicity (Aboriginal vs.
non-Aboriginal). All p-values were two-sided.
Results
Between May 1, 1996 and November 30, 2005, 1,603 par-
ticipants were recruited, including 584 (36.4%) women
and 435 (27.1%) people who reported Aboriginal ances-
try. At baseline, the median age of the participants was
33.0 (IQR = 26.0–40.0). The proportion of respondents at
baseline and each follow-up period who reported incar-
ceration in the previous six months is presented in Fig 1.
Among the study participants, 147 (9.2%) individuals
reported an incarceration event and completed a follow-
up survey both before and after the event. Of the remain-
der, 742 (46.3%) did not report an incarceration event at
identical follow-up periods; they were included in the
matched control group. Participants in the matched con-
trol group had a median age of 35.5 (IQR: 28.8 – 41.3),
significantly older than the incarceration group (median
age: 33.4, IQR: 26.3 – 39.0, p-value < 0.01). The groups
did not differ significantly with respect to gender or eth-
nicity. In tests comparing individuals included as cases or
controls to cohort participants not included in the analy-
ses, we found those individuals not included were signifi-
cantly younger (median age at baseline of 30.0, IQR =
23.9 – 37.7 compared to median age at baseline of 35.1,
IQR = 28.0 – 41.1, p < 0.001) and more likely to be female
(39.2% compared to 32.9%, p = 0.01). The observed dif-
ference in the proportions of individuals reporting aborig-
inal ancestry (24.6% among non-included compared to
29.1%) was not statistically significant (p = 0.051).
The proportion of each group reporting HIV risk factors in
each period, as well as the result of McNemar's test assess-
"Prevalence of individuals reporting incarceration in the previous six months at baseline and each follow-up period in VIDUS" Figure 1
"Prevalence of individuals reporting incarceration in the previous six months at baseline and each follow-up 
period in VIDUS".BMC Public Health 2009, 9:156 http://www.biomedcentral.com/1471-2458/9/156
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ing whether the proportions within groups were equal, is
reported in Table 1. No significant differences between the
before and after period were observed for either the incar-
cerated or control group in the prevalence of frequent
speedball injection, living in unstable housing, being
denied addiction treatment, public drug use or consistent
condom use with regular or casual sexual partners (all p >
0.05). Thus, these factors were not included in the linear
growth curve analyses. For frequent cocaine injection, a
significant decrease was observed in the control group (p
< 0.001); the decrease among the incarcerated group was
not statistically significant. A statistically significant
decrease in needing help injecting was observed in both
the incarcerated and control group (both p < 0.001). For
binge drug use, a statistically significant decrease was
observed in both the incarcerated (p < 0.005) and control
(p < 0.001) groups. Fewer individuals in both the incarcer-
ated (p = 0.016) and control (p = 0.011) groups reported
living in the DTES. A significantly lower proportion of
individuals reported participating in the sex trade in the
incarcerated (p = 0.012) and matched (p < 0.001) groups.
A statistically significant decrease in the prevalence of
syringe sharing was observed in the non-incarcerated
group (p < 0.001); the decrease in the incarcerated group
was not statistically significant (p = 0.398).
The results of the linear growth curve analyses are pre-
sented in Table 2. In models adjusted for age, gender and
Aboriginal ethnicity, no significant differences were found
in the prevalence of frequent cocaine injection (p  =
0.737); needing help injecting (p = 0.201); binge drug use
(p = 0.273); living in the DTES (p = 0.105) or participation
in the sex trade (p = 0.623) before and after a period of
incarceration compared to a matched control group.
However, in the linear growth curve analysis of syringe
sharing, a significant difference (p = 0.033) was observed
between the slopes for the incarcerated and control
groups, indicating a significant decrease in prevalence in
the control group but no significant decrease in the incar-
cerated group.
Discussion
In this analysis, we found individual, social and structural
risk factors for HIV infection were common among active
IDU both before and after periods of incarceration. In a
linear growth curve analysis, individuals recently released
from prison were significantly more likely to report shar-
ing contaminated sharing syringes as compared to indi-
viduals who did not report incarceration.
This finding sheds further light on the relationship
between incarceration and the ongoing HIV epidemic
among IDU in this setting. Both qualitative[44] and quan-
titative [32-34] findings from two prospective cohorts of
IDU in Vancouver have confirmed the link between incar-
ceration and an elevated risk of infection. [31,34] In a lon-
gitudinal analysis of incident cases, individuals reporting
incarceration were more than twice as likely to become
infected with HIV;[34] incarceration was also independ-
ently associated with syringe sharing. [32,33] As a result of
these risks and the high prevalence of incarceration
among local IDU,[32] 21% of HIV cases in the Vancouver
outbreak are estimated to be the result of imprisonment.
[45]
Although we were unable to determine the exact nature of
the relationship, these findings suggest that some aspect
of the environment or experience of incarceration leads to
a greater risk of syringe sharing once individuals are
Table 1: Risk factors for HIV infection among incarcerated cases 
(n = 147) before and after a period of incarceration compared to 
matched controls (n = 742)
Risk factor Before After p-value*
n % n %
Frequent cocaine injection
Incarcerated 46 31.3 37 25.2 0.170
Matched control 205 27.6 150 20.2 < 0.001
Frequent speedball injection
Incarcerated group 12 8.2 17 11.6 0.297
Matched control 70 9.4 67 9.0 0.748
Need help injecting
Incarcerated group 46 31.3 27 18.4 0.001
Matched control 202 27.2 142 19.1 < 0.001
Binge drug use
Incarcerated group 66 44.9 45 30.6 0.005
Matched control 271 36.5 210 28.3 < 0.001
Unstable housing
Incarcerated group 100 68.0 101 68.7 0.889
Matched control 418 56.3 414 55.8 0.806
Denied addiction treatment
Incarcerated group 24 16.3 19 12.9 0.411
Matched control 95 12.8 81 10.9 0.230
Resident in the DTES
Incarcerated group 96 65.3 78 53.1 0.016
Matched control 377 50.8 343 46.2 0.011
Public drug use
Incarcerated group 32 21.8 22 15.0 0.114
Matched control 116 15.6 110 14.8 0.602
Sex trade participation
Incarcerated group 36 24.5 25 17.0 0.012
Matched control 154 20.8 116 15.6 < 0.001
Syringe sharing
Incarcerated 38 25.9 33 22.5 0.398
Matched control 231 31.3 133 17.9 < 0.001
Condoms w/casual partners
Incarcerated 27 18.4 23 15.7 0.505
Matched control 116 15.6 103 13.9 0.312
Condoms w/regular partners
Incarcerated 30 20.4 28 19.1 0.739
Matched control 133 17.9 113 15.2 0.121
* p-value associated with McNemar's test of equalityBMC Public Health 2009, 9:156 http://www.biomedcentral.com/1471-2458/9/156
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released from custody. Many previous analyses from this
setting and others have identified a greater risk of syringe
sharing among imprisoned individuals compared with
analagous samples of IDU, especially in correctional envi-
ronments where access to sterile syringes is forbidden.
[10,32] In the current analysis, perhaps individuals
exposed to correctional environments are normalized to
the practice while incarcerated and continue once
released. [44] It is also possible that the uncertainty and
instability that characterizes the immediate post-release
period interrupts access to or use of harm reduction serv-
ices. Among non-incarcerated individuals, the decreased
level of syringe sharing observed might be related to the
expansion of opioid substitution therapies and other
harm reduction services in this setting, including the
opening of a supervised injection facility. [46] Given the
observational nature of our analyses, our current findings
are exploratory and should spur further research to evalu-
ate these hypotheses pertaining to post-release sharing.
To our knowledge, this is the first analysis to evaluate the
effect of incarceration on post-release rates of syringe shar-
ing. Two previous studies measured the prevalence of
syringe sharing following release from prison in Bangkok,
Thailand[2] and New South Wales, Australia. [47] In Thai-
land, HIV-positive cases were significantly more likely
(AOR = 2.9, 95% Confidence Interval: 1.7 – 5.0) to report
borrowing syringes in the month following incarceration
compared to HIV-negative controls. In Australia, a larger
proportion of HIV-positive cases (20%) than HIV-nega-
tive controls (15%) reported syringe sharing after dis-
charge from prison. However, in neither study could the
effect of incarceration be determined as a non-incarcer-
ated control group was not included; the comparison
group was constructed by serostatus. In our study, the use
of a non-incarcerated control group allowed the identifi-
cation of the independent effect of imprisonment.
We did not observe an effect of imprisonment on any of
the risk factors also classified as crimes in our setting,
including participation in the sex trade and illicit drug use.
This is in line with previous analyses that found many
IDU resume drug use following release[48] and that there
is no empirical evidence to support the use of enforce-
ment to reduce the population prevalence of drug use.
[49]
These findings suggest a need for a number of policy
reforms. As urged by other authors, we suggest that polit-
ical and criminal justice interventions that seek to reduce
drug use through law enforcement should be considered
in light of our findings and others linking imprisonment
and a greater likelihood of HIV risk behaviours.
[4,32,33,44] On a practical level, federal and provincial
prison authorities should expand the in-prison availabil-
ity of methadone maintenance therapy, recently shown in
a randomised control trial to improve treatment and drug-
use outcomes for recently-released prisoners,[50] and pro-
mote post-release support and referral to harm reduction
opportunities, including needle exchange, addictions
treatment and the city's supervised injection facility.
This study has methodological limitations to consider
when evaluating the findings. First, VIDUS is not a random
sample, although it is believed to be representative of the
local population of IDU. Second, although several of the
Table 2: Linear growth curve analyses of HIV risk factors modelled as outcome, adjusted for age, gender and ethnicity (Aboriginal vs. 
non-Aboriginal)
Risk factor Slope (95% Confidence Interval) p-value
Frequent cocaine injection
Incarcerated -0.342 (-0.792, 0.107) 0.737
Matched control -0.403 (-0.595, -0.212)
Need help injecting
Incarcerated -0.777 (-1.218, -0.335) 0.201
Matched control -0.467 (-0.665, -0.269)
Binge drug use
Incarcerated -0.630 (-1.047, -0.212) 0.273
Matched control -0.373 (-0.584, -0.162)
Resident in the DTES
Incarcerated -0.574 (-1.007, -0.142) 0.105
Matched control -0.185 (-0.328, -0.042)
Sex trade participation
Incarcerated -0.575 (-1.041, -0.109) 0.623
Matched control -0.398 (-0.609, -0.186)
Syringe sharing
Incarcerated -0.217 (-0.657, 0.224) 0.033
Matched control -0.722 (-0.933, -0.512)BMC Public Health 2009, 9:156 http://www.biomedcentral.com/1471-2458/9/156
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surveyed behaviours may be under- or over-reported due to
social desirability, we do not believe they were differen-
tially reported by incarceration history. Although informa-
tion on HIV serostatus is available for all participants, the
number of incident infections during the study period
among individuals included as cases or controls is too low
to allow for a valid statistical analysis; thus, we have used
measures of HIV risk to evalute the possible effects of incar-
ceration on post-release transmission patterns. Most
importantly, there may be differences between recently
incarcerated and non-incarcerated IDU that we were una-
ble to account for in multivariate analyses. Finally, we were
not able to include the length or location (i.e., municipal,
provincial or federal) of incarceration events, nor the
number of incarceration events lifetime or during the study
period, in these analyses.
Conclusion
To conclude, we evaluated the prevalence of independent
risk factors for HIV infection before and after incarcera-
tion among active IDU, and, after comparison with a
matched control group, observed a statistically significant
relationship between syringe sharing and the post-release
period. We did not find any association between incarcer-
ation and the frequency of other individual, social and
structural factors, including those also defined as crimes.
These findings point to the need for the ongoing develop-
ment of programs both within and following prison that
aim to reduce risk behaviour among IDU exposed to cor-
rectional environments.
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